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Introduction {#sec005}
============

Rheumatic heart disease (RHD) affects an estimated 33 million people globally \[[@pone.0237924.ref001], [@pone.0237924.ref002]\], making it the most commonly acquired heart disease in people \<25 years and almost as prevalent as human immunodeficiency virus \[[@pone.0237924.ref003]\]. Although the incidence of RHD in high-income countries decreased markedly during the 20th century, it remains a major public health concern in many low-and middle-income countries and marginalized communities in high-income countries--as such, three out of four children \<15 years grow up in parts of the world where RHD is endemic \[[@pone.0237924.ref001]\].

RHD is characterized by chronic valvular lesions and is the result of Acute Rheumatic Fever (ARF), which develops as an autoimmune response to Group A Streptococcal (GAS) infection \[[@pone.0237924.ref004]\]. Currently, there is no curative treatment. The secondary prophylaxis consisting of benzathine penicillin G injections every 3--4 weeks is used to prevent recurrences, which can lead to new valvular lesions or to worsening of the previous one \[[@pone.0237924.ref005]\].

Despite knowing the etiologic agent, there are still many unanswered questions regarding pathophysiologic mechanisms involved in disease development and progression. The presence of residual autoreactive cells appears to play a role in the persistence and worsening of the valvular lesions in RHD patients \[[@pone.0237924.ref006], [@pone.0237924.ref007]\]. Not all GAS are rheumatogenic, and not all people are susceptible to developing ARF and RHD. While it is not known what makes a host susceptible \[[@pone.0237924.ref008]\], it is generally accepted that malnutrition has a great impact on the immune system affecting both innate and acquired immunity in children \[[@pone.0237924.ref009]\]. More specifically, hypovitaminosis D has been associated with an increased risk of infections such as GAS pharyngitis as well as the risk of developing autoimmune diseases \[[@pone.0237924.ref010], [@pone.0237924.ref011]\]. Links have also been demonstrated with ARFand rheumatic mitral stenosis \[[@pone.0237924.ref012], [@pone.0237924.ref013]\].

Finally, extravasation through the valvular endothelium seems to be an important step in the valvular lesions seen in RHD, and since s-25(OH)D regulates expression of vascular endothelial growth factor, this could explain the link between hypovitaminosis D and endothelial dysfunction, and subsequently ARF and RHD \[[@pone.0237924.ref014], [@pone.0237924.ref015]\].

Nepal is situated in a region with one of the highest prevalence rates of RHD in the world \[[@pone.0237924.ref002]\]. A school-based study estimated prevalence of subclinical RHD to be 10.2 per 1000 children \[[@pone.0237924.ref016]\]. Prevalence estimates for adults are not available from Nepal, despite peak prevalence usually occuring between 25--45 years of age. Nonetheless, RHD remains endemic in Nepal and the South-Asian region. Prevalence of insufficient Vitamin D levels in Nepal vary from 59.8% amongst new mothers to 17.2% in 6-8year olds \[[@pone.0237924.ref017], [@pone.0237924.ref018]\]. In healthy school-children in neighboring India, vitamin D deficiency prevalence is estimated to 35% \[[@pone.0237924.ref019]\]. To date, nutritional status in ARF/RHD patients in Nepal is unknown.

In this study we examined possible associations between s-25(OH)D levels and RHD status in Nepal. In addition, associations between socioeconomic factors and RHD is also investigated.

Methods and materials {#sec006}
=====================

Study design and area {#sec007}
---------------------

This case-control study was carried out in the two largest cities in Nepal, Kathmandu and Pokhara, which are located in the Central and Western region of the country. Study participants were recruited from two hospitals; Western Regional Hospital (WRH) in Pokhara and Manmohan Cardiothoracic Vascular and Transplant Center (MCVTC) in Kathmandu, between March and July 2018. Both are governmental run health facilities, and have provided free prophylactic treatment to RHD patients through the national RHD control program funded by the Nepalese government from 2007 to 2018. MCVTC also provides free cardiac surgery for RHD patients, approximately 300 cases annually. The institutions are two of the largest governmental run health facilities in the country, and hence receive patients from all regions and districts.

Subjects {#sec008}
--------

Cases were selected from registries under the National ARF/RHD Prevention and Control Program when patients were seen for delivery of secondary prophylaxis, diagnostic and follow-up clinical evaluation or for surgical intervention. Patients were included based on a confirmed diagnosis of RHD by echocardiographic screening leading to registration in the national RHD Program Registry or new echocardiographic findings confirming RHD diagnosis, both in accordance with the World Heart Federation echocardiographic guidelines \[[@pone.0237924.ref005]\]. Exclusion criteria were issues which could interfere with Vitamin D metabolism or with the immunological conditions such as; patients below five years of age, recent hospitalization for more than one week, burn victims, chronic kidney disease and current tuberculosis or thyroid disease (self-reported).

Controls were selected by echocardiography and self-reported medical history among any people attending either institution as patients, relatives or acquaintants, matched on sex and age (maximun difference of 5 years). Exclusion criteria of controls were: diagnosis of ARF, RHD, congenital heart disease, any echocardiographic findings of valvular damage and otherwise the same exclusion criteria as for cases. Patients with congenital heart disease were excluded as they can display abnormal vitamin D concentrations \[[@pone.0237924.ref020], [@pone.0237924.ref021]\]. Cases were matched with controls from the same institution as themselves.

Collection of socio-demographic information {#sec009}
-------------------------------------------

Face-to-face interviews were conducted with all participants using a structured questionnaire containing questions on household items and living circumstances ([S1 File](#pone.0237924.s002){ref-type="supplementary-material"}). Socioeconomic status was assessed by computing a wealth index using principal components analysis. This divided the participant into terciles; poorest, middle and richest. The components used in the wealth index were; ownership of a house, animals, vehicles and electronic equipment (electricity, radio, television, mobile phone, telephone, refrigerator), furniture (bed, sofa, cupboard, computer, table, chair, clock, fan, dhiki/janto), housing characteristics and fuel used for cooking. Thus, this study measures SES based on durable assets ownership and access to utilities, to accommodate the often very fluctuating income patterns seen in many low and middle incomecountries, including Nepal.

A food frequency questionnaire was also included ([S1 File](#pone.0237924.s002){ref-type="supplementary-material"}). Participants were asked to tick the number of times they had consumed the most commonly available fruit and meat, fish, soybean oil, and egg in the last week. The purpose of the fruit intake was to detect differences in variance of diet between cases and controls, and thus give an idea of the general nutritional state of the two groups. Questions regarding meat, fish, soybean oil, and egg were added due to their possible direct effect on vitamin D concentrations and RHD development, making an assessment of differences between the two groups of interest. Questions used in this study are adapted from the Nepal Demographic and Health Survey \[[@pone.0237924.ref022]\] and Piryani et al. \[[@pone.0237924.ref023]\] to ensure cultural appropriateness.

Anthropometric measurements {#sec010}
---------------------------

The following anthropometric measurements were determined: weight (kg), height (cm), age (years) and Mid-upper arm circumference (MUAC) (mm). The same weight scale and meter tape were used to measure cases and controls and measurements were performed by the same person. Shoes and heavy items of clothing were removed beforehand. Body mass index (BMI) was calculated as weight in kilogram divided by height squared in meter (kg/m^2^). MUAC was measured on the non-dominant/left arm, except in patients with left-sided hemiplegia. Measurement was done at the mid-point between the olecranon and acromion on a relaxed arm. All participants were checked for pitting edema.

Biochemical measurements {#sec011}
------------------------

Blood was collected as dried blood spots on Perkin Elmer 226 Five Spot RUO Card filter paper, and extracted samples analyzed at the Department of Clinical Biochemistry, Aarhus University Hospital. We measured serum 25-hydroxyvitamin D2 (25(OH)D2, ergocalciferol) and serum 25-hydroxyvitamin D3 (25(OH)D3, cholecalciferol) using liquid chromatography-tandem mass spectrometry on Sciex Triple Quad 5500 LCMSMS System calibrated using 25-OH-Vitamin D3/D2 Serum calibration standards (ChromSystems). The method is adapted from Kvaskoff et al. \[[@pone.0237924.ref024]\], and S-25(OH)D is expressed as the sum of 25(OH)D2 and 25(OH)D3. Vitamin D deficiency was divided into three categories following Danish national standards, defined as: Vitamin D insufficiency (VDI) as a serum concentration between 25--50 nmol/L, moderate vitamin D deficiency (VDD) as a serum concentration of 13--25 nmol/L and severe Vitamin D deficiency as concentrations \<13 nmol/L. For some analysis the term hypovitaminosis was used, defined as all concentrations \< 50 nmol/l.

Sample size {#sec012}
-----------

The prevalence of s-25(OH)D levels below 50 nmol/l was set to 77% in RHD patients based on previous studies \[[@pone.0237924.ref012]\]. Since data on vitamin D deficiency in Nepal is very inconsistent, we hypothesized hypovitaminosis D prevalence in non-RHD individuals to be 35%, based on results from a large study from Northern India \[[@pone.0237924.ref019]\]. We estimated sample size for two independent proportions with a 95% confidence level, 90% power and a margin of error (alpha) 5% to be 64; 32 cases and 32 controls.

Statistical analysis {#sec013}
--------------------

Data were collected in hard copies and entered using REDCap electronic data capture tools. Statistical analysis was performed using Stata Statistical Software IC 15.1 (StataCorp LP, TX). Two-tailed p-values p ≤ 0.05 were considered statistically significant.

Normality in distribution was tested using q-q plots. Normally distributed continuous variables were compared between groups using Student's t-test and reported as means with standard deviation (SD). Differences between groups of categorical variables were compared using Chi-square test. SES was calculated by creating wealth index scores for each participant using principal components analysis (PCA), following the *Measuring Equity with Nationally Representative Wealth Quintiles* guide \[[@pone.0237924.ref025]\]. Due to the smaller sample size in this study compared to large epidemiological surveys, quintiles were converted into terciles. Multivariate conditional logistic regression analysis between sufficient Vitamin D concentrations and hypovitaminosis D were performed, adjusting for potential confounders; age, sex, BMI, education, and SES \[[@pone.0237924.ref026]--[@pone.0237924.ref032]\]. Potential confounders were identified a priori through a literature review. Paired 1:1 matching between cases and controls was performed after data collection, except 5 cases and 1 control who were 2:1 matched, because of the post hoc exclusion of 12 subjects ([Fig 1](#pone.0237924.g001){ref-type="fig"}). A sensitivity analysis of available variables before and after excluding the 12 subjects revealed no difference in major (or other) variables.

![Flowchart of inclusions and exclusions.](pone.0237924.g001){#pone.0237924.g001}

Ethical considerations {#sec014}
----------------------

This study received ethical approval from the ethical review board of the Nepal Health Research Council (ref. no. 2398). Written information was handed out to participants and relatives in Nepal's official language Nepali. Prior to data collection, an informed consent form had to be signed. If illiterate, oral information was given and fingerprint was used as signature. Informed assent form was obtained from participants under 18 years of age. After biochemical analysis, all results were reported back to the participants along with advice of treatment if needed. This was done by local health personnel in Nepali language.

Results {#sec015}
=======

A flowchart illustrating exclusions for the different steps in data analysis is illustrated in [Fig 1](#pone.0237924.g001){ref-type="fig"}. The study excluded 6 cases because they were misclassified as having RHD when in fact their echocardiography report revealed no significant disease. Later, an additional 6 people were excluded before any analysis regarding s-25(OH)D concentrations were performed because these 6 had comorbidities assessed to potentially affect their s-25(OH)D concentrations. They could still be part of SES calculation, dietary intake, and other demographic measures since their comorbidities would not influence these parameters.

In total, 99 patients with confirmed RHD diagnosis and 97 matched controls were included from two different sites in Nepal. A comparison of unadjusted sociodemographic, anthropometric and socioeconomic differences is presented in [Table 1](#pone.0237924.t001){ref-type="table"}.

10.1371/journal.pone.0237924.t001

###### Sociodemographic characteristics of cases and controls.

![](pone.0237924.t001){#pone.0237924.t001g}

                                                RHD Patients \[n = 99\]   Controls \[n = 97\]        P for difference
  --------------------------------------------- ------------------------- -------------------------- ------------------
  Female %                                      77%                       71%                        0.500
  Age (y), n (%)                                                                                     
   5--19                                        13 (13)                   12 (12)                    
   20--29                                       28 (28)                   28 (29)                    
   30--39                                       40 (41)                   36 (37)                    
   40--49                                       10 (10)                   12 (12)                    
   \>50                                         8 (8)                     9 (10)                     
                                                                                                     0.976
  Mean age (y) ±SD                              31 ± 11.4                 32 ± 11.6                  0.700
  Mean BMI (kg/m^2^) ±SD                        22.2 ± 4.4                24.2 ± 4.6                 0.002
  Mean MUAC mm ± SD                             252 ± 34                  266 ± 43                   0.013
  Socioeconomic status, n (%)                                                                        
   Poorest                                      46 (47)                   20 (21)                    
   Middle                                       27 (28)                   38 (39)                    
   Richest                                      25 (25)                   39 (40)                    
                                                                                                     0.001
  Number of siblings mean ± SD                  4.2 ± 2.4                 3.8 ± 2.1                  0.300
   Sisters                                      2.3 ± 2.0                 1.9 ± 1.5                  0.120
   Brothers                                     1.8 ± 1.4                 1.9 ± 1.4                  0.770
  Sleeping arrangement                                                                               
   Bed                                          83                        82                         
   Blanket/mattress on floor                    14                        15                         
                                                                                                     0.959
  People sleeping in same room (overcrowding)                                                        
   1--2                                         14                        15                         
   3--6                                         82                        79                         
   7--10                                        2                         3                          
                                                                                                     0.867
  Heart disease in family                       11                        11                         
   RHD                                          5                         5                          
   CHD                                          2                         0                          
   Other                                        4                         6                          
                                                                                                     0.301
  ARF in family                                 10                        15                         0.590
  Family type                                                                                        
   Nuclear                                      29                        34                         
   Joint                                        61                        60                         
                                                                                                     0.789
  Mean s-25(OH)D (range) \[n\]                  38.7 (8.7--89.4) \[97\]   44.7 (14.5--86.7) \[93\]   0.014

Characteristics of 99 rheumatic heart disease patients and 97 controls. SD: Standard Deviation; BMI: body-mass-index, kg/m^2^; MUAC: middle-upper-arm circumference, mm; RHD: rheumatic heart disease; CHD: congenital heart disease; RF: rheumatic fever.

The mean age of all participants was 31.71 years ± 11.5 and 75.5% were female. There was no significant difference between cases and control on gender and age.

BMI was significantly lower in cases than in controls, 22.4 ±4.5 kg/m^2^ and 24.2 ±4.6 kg/m^2^, respectively. Mean MUAC for cases were 253 ±34 mm and 266 ±43 mm for controls.

Almost half (47%) of cases belonged to the lowest possible SES class. For controls, this number was 21%. In the highest SES class, 25% of cases were represented compared to 40% of controls. The cases did not differ significantly on any other sociodemographic variables including overcrowding, compared to their controls.

We observed VDI and VDD in 78% of cases and mean concentration was significantly lower compared to controls. The prevalence of VDI and VDD in controls were 70%. [Fig 2](#pone.0237924.g002){ref-type="fig"} displays the distribution of s-25(OH)D concentrations in all groups.

![Distribution of s-25 (OH)D concentrations.\
(A) Distribution of s-25(OH)D concentrations in cases and controls with mean and standard deviation. (B) Distribution of rheumatic heart disease patients and healthy controls with severe Vitamin D deficiency (\<12 nmol/l), Vitamin D deficiency (12--25 nmol/l), Vitamin D insufficiency (25--50 nmol/l) and sufficient (\>50 nmol/l) s-25(OH)D levels.](pone.0237924.g002){#pone.0237924.g002}

Univariate conditional logistic regression analysis revealed only association between Vitamin D deficiency (\<25 nmol/l) and RHD (OR = 3.14; 95% CI: 1.02--9.64) but not for Vitamin D insufficiency. However, after adjusting for potential confounders, multivatiate analysis found a significant association (OR = 2.59; 95% CI: 1.04--6.50) for Vitmain D insufficiency but a non significant association for Vitamin D deficiency ([Table 2](#pone.0237924.t002){ref-type="table"}).

10.1371/journal.pone.0237924.t002

###### Odds ratio of rheumatic heart disease diagnosis in relation to s-25(OH)D status.

![](pone.0237924.t002){#pone.0237924.t002g}

                            Unadjusted   Adjusted[^a^](#t002fn002){ref-type="table-fn"}                                                                         
  ------------------------- ------------ ------------------------------------------------ ------------------------------------------- ----------- ------------- -------------------------------------------
  s-25(OH)D \>50 nmol/l     Reference                                                                                                 Reference                 
  s-25(OH)D 50--25 nmol/l   1.61         0.78--3.33                                       0.20                                        2.59        1.04--6.50    0.04[\*](#t002fn001){ref-type="table-fn"}
  s-25(OH)D \<25 nmol/l     3.14         1.02--9.64                                       0.05[\*](#t002fn001){ref-type="table-fn"}   3.62        0.93--14.09   0.06

\* Statistically significant *p-values*.

^a^ Adjusted for: age, BMI, sex, education, and SES.

Unadjusted (left) and adjusted (right) Odds Ratio of RHD diagnosis in relation to s-25(OH)D status. Sufficient Vitamin D status used as a reference value.

Detailed echocardiography report was available from 41 patients. Upon Chi-squared test of the report from the 41 patients available, there was no correlation between the disease stage and lower s-25(OH)D concentrations. The same was applicable when the patients without detailed echocardiographic reports were distributed into the s-25(OH)D categories considered sufficient, VDI and VDD and showed the same pattern of distribution.

Analysis of the food-frequency questionnaire revealed no statistically significant differences in intake between cases and controls ([Table 3](#pone.0237924.t003){ref-type="table"}).

10.1371/journal.pone.0237924.t003

###### Dietary intake in the last week stratified by cases and controls.

![](pone.0237924.t003){#pone.0237924.t003g}

                        RHD patients   Controls   P value
  --------------------- -------------- ---------- ---------
  Fruit intake, n (%)                             
   Not consumed         19 (19)        11 (11)    
   1 time/week          7 (7)          14 (15)    
   2--6 times/week      47 (48)        46 (47)    
   \> 7 times/week      26 (26)        26 (27)    
                                                  0.216
  Meat, n (%)                                     
   Not consumed         10 (10)        7 (7)      
   1 time/week          37 (38)        35 (36)    
   2--6 times/week      44 (45)        46 (47)    
   \> 7 times/week      7 (7)          9 (10)     
                                                  0.832
  Egg, n (%)                                      
   Not consumed         30 (31)        27 (28)    
   1 time/week          26 (26)        19 (20)    
   2--6 times/week      32 (33)        41 (42)    
   \> 7 times/week      10 (10)        10 (10)    
                                                  0.503
  Soybean Oil, n (%)                              
   Not consumed         44 (45)        40 (41)    
   1 time/week          8 (8)          3 (3)      
   2--6 times/week      19 (19)        18 (19)    
   \> 7 times/week      27 (28)        36 (37)    
                                                  0.287
  Fish, n (%)                                     
   Not consumed         59 (60)        62 (64)    
   1 time/week          30 (31)        25 (26)    
   2--6 times/week      9 (9)          10 (10)    
   \> 7 times/week      0 (0)          0 (0)      
                                                  0.750

Dietary intake in last one week, in rheumatic heart disease patients and controls.

Discussion {#sec016}
==========

Both RHD patients and controls in Nepal have a high prevalence of vitamin D deficiency and insufficiency. RHD patients on average have a significantly lower s-25(OH)D concentration compared to their controls. Especially, the prevalence of VDD was higher in RHD patients. This is to date the largest study on Vitamin D and RHD. Three other studies have examined the relationship between vitamin D concentrations and RF or RHD \[[@pone.0237924.ref012], [@pone.0237924.ref013], [@pone.0237924.ref033]\]. The previous studies showed a 27--59% lower concentration in patients whereas we only demonstrated a 12.9% difference. However, Yusuf et al. only included RHD patients, no healthy controls, and only looked at calcification (Wilkins calcium score) of exclusively stenotic mitral valves \[[@pone.0237924.ref033]\]. Onan et al. only included patients with rheumatic mitral stenosis \[[@pone.0237924.ref013]\] and the third study only included ARF patients and none with RHD \[[@pone.0237924.ref012]\]. Since inclusion criteria vary between studies, it is not surprising that results also vary. Worth noting is the fact that they all have the same conclusion: s-25(OH)D is significantly lower in patients with RHD. However, it is not possible to report on the causality of this relationship. Vitamin D status can change throughout time, making it difficult to say if the lower concentration was present before the patient developed RHD. For instance, the chronically ill RHD patient may not be active and going outside as much as before falling ill, thus being less exposed to sunlight which might explain a lower s-25(OH)D concentration. To address these questions a longitudinal study is required. Unfortunately, such data is not available from the study area, and current status is here accepted as a compromise.

To make sense of these findings, an understanding of the pleiotropic nature of Vitamin D is important. Vitamin D receptors (VDR) and the activating enzyme 1α-hydroxylase are identified in over 30 target organs including many cells of the immune system \[[@pone.0237924.ref034]\]. In the innate immune system, vitamin D enhances macrophages' phagocytic abilities and monocytes increase expression of 1α-hydroxylase and VDR through toll-like receptor signaling when encountering pathogens. The VDR complexes, in turn, activate transcription of antimicrobial cytokines \[[@pone.0237924.ref010]\]. Vitamin D also affects the adaptive immune system by modulation of antigen presenting cells to a more immature state, expressing fewer major histocompatibility complex class II molecules and thereby presenting fewer antigens and producing less interleukin-12, resulting in reduced activation of B and T cells. Furthermore, the modulated antigen presenting cells produce more interleukin-10---a tolerogenic cytokine \[[@pone.0237924.ref035]\]. Altogether, Vitamin D enhances the body's resistance against infections while decreasing the risk of an inappropriate autoimmune response. In general, RHD patients to a greater extent suffer from malnutrition with both lower BMI and MUAC. Whether they were malnourished before becoming ill or malnourished because they were ill, is not possible to determine from this study. It could be part of a two-way causal relationship as undernutrition lower immune responses, thereby increasing the risk of infection, and infection consequently aggravating undernutrition by an increase in demands of nutrients while simultaneously decreasing appetite in the affected individual \[[@pone.0237924.ref009]\].

Overcrowding and social disadvantage are two of the most commonly reported risk factors for GAS infection leading to the first espisode of ARF in susceptible individuals as well as resulting in recurrences in RHD patients \[[@pone.0237924.ref036]\]. This study also demonstrated a clear association between low SES and RHD but did not find an association with overcrowding. This could be because the mean age of patients was 31 years. Since the first acute episode of ARF occurs more frequently in the age group of 5--14 years \[[@pone.0237924.ref037]\], this means their housing situation could have changed since their childhood and adolescent years when overcrowding contributed for a higher risk of exposure to GAS and triggered ARF in those susceptible individuals. On the other hand, in Nepal, it is not unusual to live as a joint family throughout life, as demonstrated in [Table 1](#pone.0237924.t001){ref-type="table"}.

We found slightly higher s-25(OH)D concentrations in samples collected from MCVTC compared to samples from WRH. However, geographical plottings showed that participants from both institutions represent both central and peripheral districts, and the difference between patients and controls was still present when comparing the groups within the two institutions.

No association was found between dietary intake and RHD ([Table 3](#pone.0237924.t003){ref-type="table"}). This is in contrast to the general acceptance of fish and meat products as an important source of Vitamin D \[[@pone.0237924.ref038]\], as well as previous studies where consumption of soybean oil and egg, has been shown to suppress the rheumatic process because of their high concentrations of phospholipids and palmitamide \[[@pone.0237924.ref039]\].

Finally, we would like to highlight that the majority of RHD patients were young women. Though not surprising, it is still an important aspect that raises concern especially since the age of the women coincides with childbearing age. Having a heart disease, including RHD, whilst becoming pregnant can lead to serious complications \[[@pone.0237924.ref040]\]--particularly when access to health care is limited. In fact, RHD has been suggested a leading cause of indirect obstetric death in some sub-Saharan countries \[[@pone.0237924.ref030]\]. Yet no one has been able to explain why women are more often affected by RHD than men \[[@pone.0237924.ref027], [@pone.0237924.ref028], [@pone.0237924.ref030]\]. It is worth noting that this difference is not present when comparing ARF prevalence. Explanations to this sex-based difference could include extrinsic factors such as reduced access to primary and secondary ARF prophylaxis for girls and culturally rooted disadvantages affecting female health in general. Additionally, intrinsic factors increasing host susceptibility such as immunogenic, genetic and in particular hormonal differences, should also be considered and investigated further.

This study has some limitations. The major limitation being the usage of current vitamin D status as a proxy for previous concentrations. Furthermore, the higher than expected prevalence of hypovitaminosis D in the background population reduces the power of the study. However, the impact was limited by including 3 times as many participants than required in the sample size calculations. Nonetheless, the sample size is relatively small. This should also be considered when understanding the measurement of associations. While some are statistically significant, they are largely marginal. This reduces the immediate clinical applicability of the results, but should be seen in light of the aforementioned smaller sample size. Increasing the sample size for future studies could help make the associations clearer.

The dried blood spot sampling procedure for vitamin D concentration was validated twice--once before and once after data collection---at Aarhus University Hospital, using the exact same method as in this study, hence the sampling procedure should not be a considerable source of error. Furthermore, all anthropometric data were measured upon inclusion and not self reported or taken from previous examinations, adding value to the results.

However, the lack of systematic record keeping in the Nepalese health system made identification of comorbidities a challenge. All participants were questioned about their medical history and whenever possible, their record books were examined thoroughly, but on many occasions, the patients did not bring their record books, which could result in underreporting of comorbidities that might affect s-25(OH)D concentrations. Additionally, there is a risk of recall bias when conducting a survey, especially the food frequency intake should be interpreted with caution.

In light of the abovementioned limitations and the very nature of the study design, we suggest caution when generalizing to other populations, but instead advise more research in the field of vitamin D deficiencies especially in low income countries, and how it affects immune responses.

Conclusion {#sec017}
==========

Both Vitamin D Insufficiency (VDI) and Vitamin D Deficiency (VDD) is highly prevalent among Rheumatic Heart Disease (RHD) patients in Nepal. RHD patients presented with significantly lower mean s-25(OH)D concentrations and overall poor nutritional status compared to the non-RHD controls. People with Vitamin D insufficiency had a higher risk (OR = 2.59) of also having RHD, underlining the potential of hypovitaminosis D being either a risk factor or feature of RHD, but longitudinal studies are needed to explore the causality of this relationship further. Larger studies among the Nepali population is also recommended to confirm the high prevalence of hypovitaminosis D found in our control group.

Other potential risk factors found in this study include low BMI, low mid upper arm circumference, low socioeconomic status, and female sex.

Supporting information {#sec018}
======================

###### STROBE checklist.
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The authors are grateful for the support from Nepal Development Society in planning and carrying out this project. Furthermore, we would like to thank the clinical staff and students at Western Regional Hospital, Pokhara and Manmohan Cardiothoracic Vascular and Transplant Center, Kathmandu, laboratory staff at Aarhus University Hospital and Mr. Kishor Pandey from Everest International Clinic and Research Center for consultancy.

10.1371/journal.pone.0237924.r001

Decision Letter 0

Gebremedhin

Samson

Academic Editor

© 2020 Samson Gebremedhin

2020

Samson Gebremedhin

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

30 Mar 2020

PONE-D-20-02934

Evaluating Vitamin D levels in Rheumatic Heart Disease Patients and Matched Controls: A Cross-sectional Study from Nepal

PLOS ONE

Dear Ms. Thorup,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Despite the claim that the cases and controls had been age-matched, the age distribution provided in Table-1 shows considerable discrepancy, especially in the age groups 15-24 and 25-34. This should be convincingly explained by the authors.It is good that the authors attempted to control for some variables (age, BMI, sex, education, and SES) in their conditional logit regression model. However, adequate information had not been given how these variables had been selected for adjustment. The decision to adjust the matching variable "age" also need to be explained. The criteria for selecting variables for adjustment should be very convincing for the readers because the association between the VD and RHD status only becomes significant after the adjustment.One of the major limitations of the study is that the vitamin D status of the study subjects was determined many years after the outcome of interest had happened. And this has not been acknowledged and discussed in the manuscript. Do you think that the current vitamin D status can be considered as a proxy indicator for the pre RHD vitamin D status?Please present the association of RHD both with Vitamin D Insufficiency and Vitamin D Deficiency so that readers could have comprehensive understanding on the relationship between the two variables.The sample size calculation appears to be confusing. What specific formula did you use for the determination of sample? What was the expected prevalence in the RHD subjects?The purpose of the ROC analysis in the study is not clear and I recommend the authors to drop this analysis and related discussions and conclusions from this paper.Please consider a sensitivity analysis to evaluate whether the decision to exclude the 12 subjects has significantly affected the conclusion of the study or not.As most of the study subjects are adults, some of the variables of the study including maternal education, maternal occupation, and type of school are less relevant and I kindly recommend you to remove them. I also don't understand the purpose of presenting HFA standard curves for boys and girls less than the age of 19 years while most of the study subjects are actually adults.The variables of the study (apart from RHD and VD status) should be clearly listed and described in the methods section.As suggested by the second reviewer, the study should be described as a case-control study.

We would appreciate receiving your revised manuscript by Apr 27 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Samson Gebremedhin, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (section-by-section comments):

Abstract

Is this sentence really relevant for the research question posed? "Diagnosis and treatment for Rheumatic Heart Disease (RHD) is inaccessible for many 26 of the 33 million people in low- and middle-income countries living with this disease" 

Background

Line 94-95: Can you rephrase the phrase "occurrence of RHD" to "RHD status" because the latter is more compatible with cross-sectional and case-control designs

Methods

Line 118: please provide your matching criteria for age. i.e. the age range considered for matching of cases and controls

Line 154: Confidence interval \> confidence level

Results

Table 1: "Less poor" \> "middle"

Table 1: The variable "Type of school" is not clear

Table 1: Please redefine age ranges based on wider intervals so that statistical test would be feasible.

Line 236-237: "Analysis of the food-frequency questionnaire revealed no statistically significant differences in intake 237 between cases and controls". The type of the food frequency questionnaire should be described in the methods section. 

Discussion

I recommend the authors to integrate the section "strength and limitation" with the discussion section.

Conclusion

Line 340: "Vitamin D status could not be used as a predictor of RHD diagnosis". To start with, was there any priori hypothesis to assume that the current vitamin D status could be used as a predictor of RHD that happened many years back?

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see <http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions>.

In your revised cover letter, please address the following prompts:

a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: A well written manuscript which is clinically relevant. Please address the following :

1\. Please explain the categories of the socioeconomic status : poorest, less poor and richest.

2\. The data on hours of TV per day is redundant and sounds unscientific. Kindly remove or explain its relevance.

3\. Please remove the figures on height for age in girls and boys. These are not part of the study objectives.

Reviewer \#2: Thank you for this well designed and written study. I have only some minor revisions for the authors to consider.

1\. The title refers to both a case control and cross section study. In my view it qualifies as a case control study and so could be simply called this. It is a point in time study, yes, but this is the nature of C-C studies where we start with the known outcome and compare exposures retrospectively. The authors could reconsider the title.

2\. Minor text edits

27-28: in order to prevent and optimise treatment. Could be made clearer that it is to prevent disease and optimise treatment.

37-38: suggest slight change to wording with addition of \'compared with\' controls instead of \'while for\'

43: add s to control

77: develop-ing

91-92: I am not sure I understand what is meant by \'Vitamin D status vary among from 59.8%\'. Could you clarify what this measurement is? e.g. low status, known status.

116: for TB and thyroid disease, was it both current and previous disease excluded or just current?

119: I am interested in why congenital heart disease patients were excluded. Other studies on RHD specifically use this population for controls. MAybe a sentence to justify this would be useful for others considering designing similar studies on RHD to help them understand your decision.

Table 3: Woudl be good to include the % as well as in Table 1.

3\. Age groups: if they were age matched, why is there a discrepancy in the age group numbers? Maybe it needs to be better explained in the methods section how you age matched so readers can understand this better.

4\. Nutritional differences: while no differences were found among males, the respective sample sizes were small. It could then be that you simply didn\'t have the power to detect a true difference among the males. This could be discussed more in your limitations section.

5\. 310-311: I think you need to add in references to other studies here that support your claims with regards to preponderance of females with RHD.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Sakthiswary Rajalingham

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 0

27 Apr 2020

Dear Dr. Samson Gebremedhin and reviewers at PLOS ONE

Thank you for your comments on our manuscript PONE-D-20-02934 entitled "Evaluating Vitamin D levels in Rheumatic Heart Disease Patients and Matched Controls: A Cross-sectional Study from Nepal". We have read your comments with great interest and revised our manuscript accordingly. As requested a version of the manuscript with marked changes as well as a version without marks have been uploaded alongside this rebuttal letter.

Comments from editor and reviewers:

Editor

\- Despite the claim that the cases and controls had been age-matched, the age distribution provided in Table-1 shows considerable discrepancy, especially in the age groups 15-24 and 25-34. This should be convincingly explained by the authors.

RESPONSE: We fully agree that the intervals set display discrepancies and have corrected accordingly with more appropriate cutoffs.

\- It is good that the authors attempted to control for some variables (age, BMI, sex, education, and SES) in their conditional logit regression model. However, adequate information had not been given how these variables had been selected for adjustment. The decision to adjust the matching variable "age" also need to be explained. The criteria for selecting variables for adjustment should be very convincing for the readers because the association between the VD and RHD status only becomes significant after the adjustment.

RESPONSE: Thank you for pointing our attention to this. We chose the selected variables based on knowledge from previous studies about RHD and Vitamin D. We have now added references on all (ref 26-32) please see section on statistical analysis for changes.

We chose to adjust for age also because of the later mentioned interval of age matching used in this study of 5 years. This makes a "frequency matching" on this specific variable, and thus we feel it would make sense to adjust in the regression analysis. By choosing conditional logistic regression analysis instead of unconditional, this should not be a cause of concern. We hope this explains the motivation behind the chosen variables sufficiently.

\- One of the major limitations of the study is that the vitamin D status of the study subjects was determined many years after the outcome of interest had happened. And this has not been acknowledged and discussed in the manuscript. Do you think that the current vitamin D status can be considered as a proxy indicator for the pre RHD vitamin D status?

RESPONSE: Thank you for pointing this out. Agreed, it has not been addressed properly. We acknowledge that current vitamin D status does not equate previous status. Ideally there would be data on Vitamin D concentrations on all subjects from very young age, but due to the nature of RF and RHD this would require data at least 30 years old in many cases. Unfortunately, this is not available in most areas affected by this disease, and thus we have to accept the current status as a compromise. It is not ideal, but at the same time we find it feasible as Vitamin D deficiency is dependent on sun exposure, which highly reflects both environmental and cultural factors. We reckon these factors would not have changed much over time in Nepal on an individual basis. Please see new paragraph added line 276-280 and 335-336.

\- Please present the association of RHD both with Vitamin D Insufficiency and Vitamin D Deficiency so that readers could have comprehensive understanding on the relationship between the two variables.

Thank you for noticing. The reason we did not present the OR of both vitamin D insufficiency and deficiency was the small number of people in the deficiency group (see Figure 2). We deemed the strength of the resulting OR weaker because of the small number, and thus decided to combine the two. However, we have made the adjustments as suggested. They are presented in a new Table 2 on page 13 in the manuscript for you to evaluate.

\- The sample size calculation appears to be confusing. What specific formula did you use for the determination of sample? What was the expected prevalence in the RHD subjects?

RESPONSE: Thank you the comment. We calculated sample size for two independent proportions. These proportions used were based on previous studies; according to ref 11 the expected prevalence in ARF/RHD is 77 %, and 35 % in non-RHD individuals according to ref 18. We hope this has been made clearer now in the sample size section.

\- The purpose of the ROC analysis in the study is not clear and I recommend the authors to drop this analysis and related discussions and conclusions from this paper.

RESPONSE: We agree it has not been fully justified to include the ROC analysis in the manuscript. It has now been removed.

\- Please consider a sensitivity analysis to evaluate whether the decision to exclude the 12 subjects has significantly affected the conclusion of the study or not.

RESPONSE: This is a good point. The initial thought was that the 12 subjects excluded because of comorbidities would not differ on other major factors. But to see if it did have an effect, we did a sensitivity analysis of available variables by including and excluding the 12 subjects. There was no difference in major (or other) variables between the two groups and we therefore assume that the result would remain the same if we had included the 12 subjects in our model.

\- As most of the study subjects are adults, some of the variables of the study including maternal education, maternal occupation, and type of school are less relevant and I kindly recommend you to remove them. I also don't understand the purpose of presenting HFA standard curves for boys and girls less than the age of 19 years while most of the study subjects are actually adults.

RESPONSE: This is an excellent point and we fully agree that this information is not very relevant for the adults. When designing the study we expected the mean age of patients to be lower than what was actually the case, and thus some of the questions were less relevant to the older participants. However, for wealth index score this information was still necessary which is why they were still included. We acknowledge that it does not make much sense to include in the table and have now removed the information accordingly. Instead a supplementary file of the questionnaire used including all variables have been uploaded as a supplement, as we feel it could still be useful information for others. They can then get the data collected on request if interested.

As for the HFA: stunting is a good proxy of chronic malnutrition. Unfortunately HFA standard curves does not exceed 19 years of age and cannot be used for adults. As pointed out earlier, the majority of the study participants are adults, but we feel the knowledge about the long term nutrition, even if only available for a minority of our subjects, is still very important. Especially when taking into consideration the aforementioned limitations in study design i.e. we do not know much other about the patient's nutritional status at the time of disease development. This is why we would like to keep the HFA on the children and adolescents we do have information on.

\- The variables of the study (apart from RHD and VD status) should be clearly listed and described in the methods section.

RESPONSE: The questionnaire with all variables can be found in the newly added supplement 1.

\- As suggested by the second reviewer, the study should be described as a case-control study.

RESPONSE: we fully agree. It has now been corrected throughout the manuscript.

Additional Editor Comments (section-by-section comments):

Abstract

Is this sentence really relevant for the research question posed? "Diagnosis and treatment for Rheumatic Heart Disease (RHD) is inaccessible for many 26 of the 33 million people in low- and middle-income countries living with this disease"

RESPONSE: Thank you for the comment. we believe so it is still important, as it sets the scene and justifies why we should investigate this disease more.

Background

Line 94-95: Can you rephrase the phrase "occurrence of RHD" to "RHD status" because the latter is more compatible with cross-sectional and case-control designs.

RESPONSE: Yes, we agree. It has been corrected.

Methods

Line 118: please provide your matching criteria for age. i.e. the age range considered for matching of cases and controls

Line 154: Confidence interval \> confidence level

RESPONSE: Thank you for pointing our attention to this. It has been changed and explained an age range for matching with a maximum of 5 years difference (line 121-122).

Results

Table 1: "Less poor" \> "middle"

Table 1: The variable "Type of school" is not clear

Table 1: Please redefine age ranges based on wider intervals so that statistical test would be feasible.

Line 236-237: "Analysis of the food-frequency questionnaire revealed no statistically significant differences in intake between cases and controls". The type of the food frequency questionnaire should be described in the methods section.

RESPONSE: Thank you. As addressed above, the intervals have been changed and the variable in question has been removed from the manuscript. Furthermore, the description is changed from fruit intake to food-frequency (line 132). We kindly refer to the questionnaire in supplementary 1 for an in-depth view of the food frequency information collected.

Discussion

I recommend the authors to integrate the section "strength and limitation" with the discussion section.

RESPONSE: thank you for the comment, we have integrated the section into the discussion as suggested.

Conclusion

Line 340: "Vitamin D status could not be used as a predictor of RHD diagnosis". To start with, was there any priori hypothesis to assume that the current vitamin D status could be used as a predictor of RHD that happened many years back?

RESPONSE: We agree that we did not make that assumption from the beginning. As the ROC analysis has been removed as suggested, we have now also removed the sentence regarding this hypothesis.

Reviewer \#1:

A well written manuscript which is clinically relevant. Please address the following :

1\. Please explain the categories of the socioeconomic status : poorest, less poor and richest.

RESPONSE: We would like to refer to reference nr 25. In short SES was estimated by calculating wealth index scores for each participant using principal components analysis (PCA). PCA assigns a specific weight to each variable which is used to summarize household wealth for a specific area and divides the study population into categories based on wealth. We chose this method instead of traditional measures such as income and consumption expenditure because we find it gives a more reliable representation of households, especially in LMICs. Unreliable income patterns with short term employments is common in Nepal, and so if collecting information in a period of unemployment, results would not be representative for the actual state of the household. Measuring wealth based on durable asset ownership and access to utilities as in the PCA analysis has the advantages of providing a long-term representation of SES, not affected by fluctuations in income. It is however a relative analysis -- it tells us about the composition of the studied population, but not about the national distribution. For a list of variables included please see supplementary 1.

2\. The data on hours of TV per day is redundant and sounds unscientific. Kindly remove or explain its relevance.

RESPONSE: Thank you for the comment. We have removed it from the manuscript and instead listed the variable in the supplementary as it was part of the SES calculation.

3\. Please remove the figures on height for age in girls and boys. These are not part of the study objectives.

RESPONSE: We kindly refer to the address of the same comment from the editor above.

Reviewer \#2:

Thank you for this well designed and written study. I have only some minor revisions for the authors to consider.

1\. The title refers to both a case control and cross section study. In my view it qualifies as a case control study and so could be simply called this. It is a point in time study, yes, but this is the nature of C-C studies where we start with the known outcome and compare exposures retrospectively. The authors could reconsider the title.

RESPONSE: Thank you for the comment. We fully agree and have changed the study design to a case-control study.

2\. Minor text edits

27-28: in order to prevent and optimise treatment. Could be made clearer that it is to prevent disease and optimise treatment.

RESPONSE: We agree, this makes more sense. It has been changed as suggested.

37-38: suggest slight change to wording with addition of \'compared with\' controls instead of \'while for\'

43: add s to control

77: develop-ing

RESPONSE: Thank you for good inputs. All 3 suggestions above have been added to the manuscript.

91-92: I am not sure I understand what is meant by \'Vitamin D status vary among from 59.8%\'. Could you clarify what this measurement is? e.g. low status, known status.

RESPONSE: We understand the problem with this sentence and has changed it to: Prevalence of insufficient Vitamin D levels in Nepal vary from 59.8 % amongst new mothers to 17.2 % in 6-8 year olds. We hope this makes more sense.

116: for TB and thyroid disease, was it both current and previous disease excluded or just current?

RESPONSE: Thank you for pointing our attention to this. Subjects were excluded if they had current disease. We have changed this in the manuscript (line 119).

119: I am interested in why congenital heart disease patients were excluded. Other studies on RHD specifically use this population for controls. Maybe a sentence to justify this would be useful for others considering designing similar studies on RHD to help them understand your decision.

RESPONSE: This is a very good point and has not been made sufficiently clear although it is important. The rationale behind excluding congenital heart disease patients were that vitamin d deficiency is more common in this group. we excluded them as they will not represent the general population in this matter. We added this explanation (line 124-125) as well as references 20-21 to support.

Table 3: Would be good to include the % as well as in Table 1.

RESPONSE: Thank you, we have added the % as suggested.

3\. Age groups: if they were age matched, why is there a discrepancy in the age group numbers? Maybe it needs to be better explained in the methods section how you age matched so readers can understand this better.

RESPONSE: Thank you for your comment. As suggested, new age intervals have been made in table 1. The was a maximum span of 5 years between cases and controls, but usually they were the same age or only 1-2 years apart.

4\. Nutritional differences: while no differences were found among males, the respective sample sizes were small. It could then be that you simply didn\'t have the power to detect a true difference among the males. This could be discussed more in your limitations section.

RESPONSE: Thank you for this very good point. We agree and have added this to the discussion as: "The lack of difference in BMI and other nutritional measures amongst males should be interpreted with care, as it could simply reflect a small proportion of males included, reducing the ability to detect a difference".

5\. 310-311: I think you need to add in references to other studies here that support your claims with regards to preponderance of females with RHD.

RESPONSE: We agree. We have added reference 28, 29, 31m that should support our claims sufficiently.

We hope our answers have been satisfactory, and we are always ready to elaborate further if needed.

Best Regards,

Lene Thorup
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7 May 2020

PONE-D-20-02934R1

Evaluating Vitamin D levels in Rheumatic Heart Disease Patients and Matched Controls: A Case-Control Study from Nepal

PLOS ONE

Dear Ms. Thorup,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 21 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Samson Gebremedhin, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

In the abstract please state the age range of the subjects.Background -- line 71-73: the sentence needs citation.Background -- line 87-95: please merge the two paragraphs.Methods: please clearly describe (i) how the dietary intake (Table 3) of the study subject was assessed. (ii) how the socioeconomic status was measured and classified.Results -- Table 1: Please report the p-values for the age categories.Results -- Line 208-11: please remove the stratified analysis by sex because the sample size is too low for meaningful sub-sample analysis.Results -- Table 2: please clearly designate significant p-values in the table. All the adjusted variables must also be shown in the table.Results -- Table 3: the table should have a comprehensive title that describe its content. In the methods section, the authors need to discuss the purpose of the food frequency data analysis.Results -- Figure 3 and 4: As commented earlier, please remove the HFA standard curves from adolescents. The sample size (n=25) is small for any meaningful analysis. Further, as this is a comparative study, merging and describing the two groups into one is practically less meaningful.Please also discuss possible reasons that may alternative explain the association. E.g. less sunlight exposure RHD patients.Please also discuss that most of the associations are borderline and may not have huge clinical significance. Further, the implication of the small sample size of the study should be discussed.

\[Note: HTML markup is below. Please do not edit.\]

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

3 Jul 2020

Additional Editor Comments

• In the abstract please state the age range of the subjects.

o Thank you, the age range has been added to the abstract as suggested.

• Background -- line 71-73: the sentence needs citation.

o The treatment regime is recommended globally and described by the World Heart Federation of which the reference now has been added. The last part about recurrences is based on personal correspondence, why a reference was not added. We have chosen to omit the sentence instead, so no confusion arises. Thank you for pointing our attention to the lack of reference here. Please see changes line 70-72.

• Background -- line 87-95: please merge the two paragraphs.

o Thank you. It has been changed in the final version.

• Methods: please clearly describe (i) how the dietary intake (Table 3) of the study subject was assessed. (ii) how the socioeconomic status was measured and classified.

o A new description has been added in the methodological section "collection of sociodemographic information". The main difference between this study and others alike, is the use of principal components analysis, we believe. A full description of this method can be seen in ref no. 25 "Measuring Equity with Nationally Representative Wealth Quintiles Guide" (please see the Statistical analysis section), but essentially it is based what is currently owned in the household of each individual and is thus giving information of the wealth of the family on a long term basis. This method is more appropriate than basing the SES on income and expenditure information, especially in the context of Nepal, as many have fluctuating and unreliable income patterns. All variables used for the calculations can be seen in Supplement 1, questions 13-17 and 20-22 were used for the SES calculations. but to make it more clear, are also listed here:

\- Own home -- rented or bought.

\- Household items: electricity, radio, television, mobile phone, telephone, refrigerator, bed, sofa, cupboard, computer, table, chair, clock, fan, dhiki/janto (a traditional grinding mill in Nepal).

\- Fuel used for cooking: electricity, LPG, biogas, kerosene, wood, animal dung, other.

\- Type of roof on house: thatched, galvanized, ceramic, cement, other.

\- No. of livestock in household: buffalo, milk cow/bull, goat, chicken, duck, pig, other.

\- Ownership of transportation equipment: Bicycle/rickshaw, motorcycle/scooter, three wheeler, car, bus or truck.

o Similarly the fruit frequency questionnaire used can be seen in supplement 1, question no. 23. The participants ticked boxes of how many times in the last week they had consumed the mentioned items, and based on this, table 3 was created. All fruits were combined in the final table, but in the questionnaire separate fruit items were mentioned, to encourage more accurate memory/information.

Most importantly, all questions have been tailored specifically for Nepal, and have all been used in previous surveys/studies in all areas of the country.

We hope this describes the process sufficiently, and likewise that you will contact us with further questions if not so.

• Results -- Table 1: Please report the p-values for the age categories.

o Thank you, it has been added to table 1.

• Results -- Line 208-11: please remove the stratified analysis by sex because the sample size is too low for meaningful sub-sample analysis.

o Thank you for pointing this out. The sub-sample analysis have been removed from the result section as asked, as well as from Table 1.

• Results -- Table 2: please clearly designate significant p-values in the table. All the adjusted variables must also be shown in the table.
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o Thank you for the comment. We have chosen to incorporate it as a possible explanation for the lower concentrations in the patients and something to look further into for future studies. Please see the discussion line 265-267.
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